ENTECAVIR (Cipla USA Inc.)
Welcome to the PulseAid listing for the ENTECAVIR drug offered from Cipla USA Inc.. This Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Cipla USA Inc. |
| NON-PROPRIETARY NAME: | ENTECAVIR |
| SUBSTANCE NAME: | ENTECAVIR |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
| ROUTE: | ORAL |
| DOSAGE FORM: | TABLET, FILM COATED |
| MARKETING CATEGORY NAME: | ANDA |
| START MARKETING DATE: | 2016-12-06 |
| END MARKETING DATE: | 0000-00-00 |
ENTECAVIR HUMAN PRESCRIPTION DRUG Details:
| Item Description | ENTECAVIR from Cipla USA Inc. |
| LABELER NAME: | Cipla USA Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 1(mg/1) |
| START MARKETING DATE: | 2016-12-06 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 69097-425_a2f0adb2-6505-47bf-ac71-e15cd38434f3 |
| PRODUCT NDC: | 69097-425 |
| APPLICATION NUMBER: | ANDA206872 |
Other ENTECAVIR Pharmaceutical Manufacturers / Labelers:
